Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check46 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a clinical trial for CD30+ lymphoma treatments and the addition of new identifiers and a location for a study. The revision number has also been updated.SummaryDifference38%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 10, 2025.SummaryDifference0.3%
- Check83 days agoChange DetectedThe page has been updated to reflect that the study is currently active and not recruiting, with new relevant dates for the study timeline. Additionally, contact information for the principal investigator has been removed.SummaryDifference3%
- Check97 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.